The Early Detection Research Network: Biomarker Referen*

描述（由申请人提供）：UCLA生物标志物参考实验室（UCLA-BRL）旨在延续和扩展已建立的EDRN资助的UCLA生物标志物验证实验室（BVL）。值得注意的是，加州大学洛杉矶分校的BVL是非常成功的建立了许多EDRN合作和构建组织微阵列资源的EDRN研究。我们的目标与EDRN的使命密切相关，包括：i）利用我们多样化的基础设施和高技能的人员来测试、评估、量化和优化生物标志物的检测，这些生物标志物是有用的早期肿瘤标志物。为此，我们建立了科学中心，可以测试组织（全组织切片或“智能”高密度组织微阵列）和液体中的生物标志物（通过传统的ELISA和纳米技术电化学芯片）。此外，我们还拥有检测体液中核酸以及组织、细胞和/或体液中DNA修饰和改变的资源。ii）开发用于生物标志物检测和分析的新平台和算法。这包括与工业合作伙伴一起开发和实施用于测量流体中生物标志物的高通量纳米检测芯片，以及使用组织微阵列挖掘生物标志物谱的内部开创性研究。iii）在加州大学洛杉矶分校继续一个高度专业和集中的计划，但同时灵活和具有成本效益，以应对不断发展的EDRN计划的挑战。iv）坚定地致力于与EDRN成员合作，团队合作以及共享资源和数据，以促进识别临床有用的早期检测生物标志物的目标。UCLA-BRL的领导能力很强，热情洋溢，并强烈致力于EDRN的目标。此外，UCLA-BRL还得到了医学院，Jonsson综合癌症中心，UCLA肺癌SPORE和UCLA前列腺癌SPORE的强大机构支持。

DESCRIPTION (provided by applicant): The UCLA Biomarker Reference Laboratory (UCLA-BRL) is designed to be a continuation and expansion of the established EDRN-funded UCLA Biomarker Validation Laboratory (BVL). Significantly, the UCLA BVL is highly successful having established numerous EDRN collaborations and constructed tissue microarray resources for EDRN investigators. Our goals are in close alignment with the mission of the EDRN and include: i) The utilization our diverse infrastructure and highly skilled personnel to test, evaluate, quantify, and optimize detection of biomarkers useful early stage tumor marker. To this end, we have established Scientific Centers that can test for biomarkers in tissue (full tissue sections or 'intelligent' high density tissue microarrays) and in fluids (by conventional ELISA and nanotech electrochemical chip). In addition, we have the resources to detect nucleic acids in body fluids as well as DNA modification and alterations in tissue, cells and/or fluids. ii) The development of new platforms and algorithms for biomarker detection and analysis. This includes the development and implementation, in conjunction with an industrial partner, of a high throughput nano-detection chip for measuring biomarkers in fluids, and in-house pioneering research on mining biomarker profiles using tissue microarrays. iii) The continuation of a program at UCLA that is highly professional and focused, yet at the same time flexible and cost-effective in order to meet the challenges of an evolving EDRN program. iv) A strong commitment to collaboration, teamwork, and sharing of resources and data with EDRN members in order to promote the goal of identifying clinically useful early detection biomarkers. The UCLA-BRL leadership is highly capable and enthusiastic, and strongly dedicated to the goals of the EDRN. Moreover, the UCLA-BRL has strong institutional support from the School of Medicine, Jonsson Comprehensive Cancer Center, the UCLA Lung Cancer SPORE, and the UCLA Prostate Cancer SPORE.